Deal Snapshot
HOUGHTON MIFFLIN HARCOURT TO SELL RIVERSIDE CLINICAL AND STANDARDISED TESTING PORTFOLIO ALPINE INVESTORS
Friday 14 September 2018

US-based text book publisher Houghton Mifflin Harcourt (HMH) (NASDAQ : HMHC) has entered into a definitive agreement to divest its Riverside clinical and standardised testing portfolio to private equity firm Alpine Investors, for a purchase price of USD 140m, the company said.
The divestiture will enable HMH to sharpen its focus on integrating best-in-class curriculum, embedded formative assessment and professional development to drive improved student outcomes.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 14/09/2018
Target: Riverside,  clinical and standardised testing portfolio
Country: USA
Deal Size: 140m (USD)
Sector: Media
Type: Corporate acquisition
Financing: Cash
Status: Agreed
Vendor: Houghton,  Mifflin Harcourt 
Buyer: Alpine Investors
Comment:


Options